This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Morton Coleman, MD
New York

Arch Intern Med. 1982;142(9):1755-1756.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is almost axiomatic that once a disease or phase of a disease has been described, the frequency of its observation virtually increases exponentially with its recognition. Indeed, the report by Suchman et al represented one of four recent publications buttressing our initial observations on the aggressive phase of myeloma.^1-4

Bergsagel and Pruzanski⁵ observed that roughly one third of the patients dying with myeloma had characteristics of the terminal phase that consisted of fever, peripheral pancytopenia, and marrow hypercellularity. The data presented by Blade et al suggested that the aggressive phase variant represents, in turn, a subset of one third of such patients or approximately 8% to 10% of all patients dying with myeloma. These data are roughly in keeping with our own preliminary observations.

The description of what constitutes the aggressive phase of myeloma may, in fact, be too restrictive. The presence of a histologic pattern suggestive . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?